Edition:
United Kingdom

Aurinia Pharmaceuticals Inc (AUP.TO)

AUP.TO on Toronto Stock Exchange

8.12CAD
13 Dec 2018
Change (% chg)

$-0.22 (-2.64%)
Prev Close
$8.34
Open
$8.34
Day's High
$8.34
Day's Low
$8.06
Volume
27,900
Avg. Vol
36,881
52-wk High
$8.65
52-wk Low
$5.68

Latest Key Developments (Source: Significant Developments)

Aurinia Pharmaceuticals Richard Glickman, Chairman And Chief Executive Officer, To Retire
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA REPORTS THIRD QUARTER FINANCIAL RESULTS, CLINICAL HIGHLIGHTS AND CORPORATE DEVELOPMENT.AURINIA PHARMACEUTICALS INC - RICHARD M. GLICKMAN, COMPANY'S CHAIRMAN AND CHIEF EXECUTIVE OFFICER, INTENDS TO RETIRE.AURINIA PHARMACEUTICALS - GLICKMAN TO RETIRE AS CEO ONCE A REPLACEMENT IS IDENTIFIED AND APPOINTED.AURINIA PHARMACEUTICALS INC - AT SEPTEMBER 30, 2018, WE HAD CASH, CASH EQUIVALENTS AND SHORT TERM INVESTMENTS OF $138.9 MILLION.AURINIA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.21.  Full Article

Aurinia Completes Enrollment Of Aurora, Its Phase 3 Clinical Trial For The Treatment Of Lupus Nephritis
Tuesday, 25 Sep 2018 

Sept 25 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA COMPLETES ENROLLMENT OF AURORA, ITS PHASE 3 CLINICAL TRIAL FOR THE TREATMENT OF LUPUS NEPHRITIS.AURINIA COMPLETES ENROLLMENT OF AURORA, ITS PHASE 3 CLINICAL TRIAL FOR THE TREATMENT OF LUPUS NEPHRITIS.AURINIA PHARMACEUTICALS INC - COMPANY ANTICIPATES PRIMARY DATA ANALYSIS IN Q4 2019.  Full Article

Aurinia reports Q3 loss per share $0.16
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Aurinia Pharmaceuticals Inc :Aurinia reports third quarter 2017 financial results and provides operational highlights.Aurinia Pharmaceuticals Inc - ‍Aurora phase III trial in lupus nephritis on track​.Q3 loss per share $0.16.Aurinia Pharmaceuticals - Believe​ co have sufficient financial resources to fund LN program,conduct work on new indications & fund operations into 2020.  Full Article

Robert Duggan reports 5.9 pct stake in Aurinia Pharmaceuticals - SEC filing‍​
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Aurinia Pharmaceuticals Inc : :Robert Duggan reports 5.9 percent stake in Aurinia Pharmaceuticals Inc as on October 19, 2017 - SEC filing‍​.Robert Duggan had previously reported 7.2 percent stake in Aurinia Pharmaceuticals Inc as on April 21, 2017.  Full Article

Aurinia Pharmaceuticals plans to expand voclosoprin renal franchise
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Aurinia Pharmaceuticals Inc :Aurinia Pharmaceuticals Inc - ‍ plans to expand voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease​.Aurinia Pharmaceuticals - ‍ plans to evaluate proprietary nanomicellar voclosporin ophthalmic solution for treatment of keratoconjunctivitis sicca/ DES.Aurinia Pharmaceuticals - ‍a phase II proof of concept clinical trial for voclosporin in FSGS and MCD patients will be initiated in first half of 2018​.  Full Article

Aurinia Pharma announces 48-week results from study of voclosporin
Monday, 27 Mar 2017 

Aurinia Pharmaceuticals Inc : Aurinia Pharmaceuticals-announces 48-week results from “Aurinia early urinary protein reduction predicts response study” of voclosporin for treatment of lupus nephritis . Aurinia Pharmaceuticals Inc says study successfully achieved primary objective - SEC filing .Aurinia Pharmaceuticals says no new safety signals were observed with use of voclosporin in ln patients; voclosporin was well-tolerated.  Full Article